Abstract
Tumor markers CA-19-9 (a carcinoembryonic antigen) and α-fetoprotein are measured in sera of 437 patients hospitalized for diseases other than cancer. The CA-19-9 level is increased in patients with peptic ulcer and cholelithiasis. The study demonstrates the advantages of immunological methods of examination in the diagnosis of latent tumors of the kidneys, stomach, pancreas, liver, gallbladder, and lungs. Tumor markers can be used as prognostic criteria in cirrhosis of the liver, chronic hepatitis, and circulatory diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yu. P. Reznikov, V. I. Ul'yanov, A. S. Varyukhin,et al., Vopr. Onkol., No. 1, 51–56 (1988).
N. A. Yal'chenko and V. D. Lagutin,Lab. Delo, No. 11, 48–52 (1991).
P. A. Humphrey,Semin. Surg. Oncol.,5, No. 3, 186–193 (1989).
H. Juhl,Hepatogastroenterology,36, No. 1, 27–32 (1989).
L. M. Molina, M. Diez, M. T. Cava,et al., Int. J. Biol. Markers,5, No. 3, 127–132 (1990).
Author information
Authors and Affiliations
Additional information
Translated fromByulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 123, No. 5, pp. 566–569, May, 1997
Rights and permissions
About this article
Cite this article
Skvortsov, S.V., Kushlinskii, N.E., Kadagidze, Z.G. et al. The carcinoembryonic antigen CA-19-9 and α-fetoprotein in patients with diseases other than cancer and their clinical significance. Bull Exp Biol Med 123, 493–495 (1997). https://doi.org/10.1007/BF02445329
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02445329